AOD9604 Dosage in the Research Literature
AOD9604 Dosage in the Research Literature
AOD9604 dosage data comes from six randomized double-blind placebo-controlled human trials conducted by Metabolic Pharmaceuticals between approximately 2001 and 2008, involving approximately 900 participants. The dosing information on this page is a summary of what was administered in those studies. It is research context, not a clinical recommendation.
Phase I: Intravenous Dose-Escalation Studies
Phase I human studies evaluated intravenous AOD9604 at doses ranging from 25 to 400 mcg/kg body weight. Primary objectives were safety, tolerability, and pharmacokinetic characterization. Across these trials, no serious adverse events were observed, no antibody formation was detected, and the adverse event profile was indistinguishable from placebo [4]. Pharmacokinetic data from pig models (the closest published proxy): IV half-life approximately 3 minutes; this rapid clearance is consistent with the peptide's small size and expected enzymatic degradation [18].
Phase IIa: Oral Dose-Ranging (METAOD005)
The Phase IIa study enrolled 300 obese patients across five sites and evaluated six oral dose groups: 0, 1, 5, 10, 20, and 30 mg/day for 12 weeks. The 1 mg/day group was the only group to show statistically significant weight loss differentiation from placebo: mean 2.8 kg versus 0.8 kg at 12 weeks [7]. Higher doses did not show a dose-response advantage — the 5–30 mg/day groups did not outperform the 1 mg group. Secondary metabolic markers at 1 mg/day showed improvement in cholesterol profiles and a reduction in participants with impaired glucose tolerance compared to placebo [21]. Based on these results, 1 mg/day was identified as the dose for Phase IIb investigation.
Phase IIb: Oral 24-Week Study (METAOD006 — OPTIONS)
The Phase IIb OPTIONS study enrolled 502 obese adults and randomized them to oral AOD9604 at 0.25 mg, 0.5 mg, or 1.0 mg per day, or placebo, for 24 weeks. No dose group demonstrated statistically significant weight loss compared to placebo at the primary 24-week endpoint [8]. The safety profile remained excellent — no serious drug-related adverse events, no antibody formation, no IGF-1 elevation, no glucose disruption. The program was discontinued in 2007 following the Phase IIb results.
Timing and Fasting Considerations in AOD9604 Research Protocols
Clinical trials administered oral AOD9604 in fasted states or at specific meal-relative times consistent with optimizing peptide absorption. The published protocols do not isolate timing as an independent variable — the fasting-state administration rationale is based on peptide absorption kinetics theory rather than direct comparative timing data in the AOD9604 literature specifically.
AOD9604 Administration: Oral vs Subcutaneous Injection
AOD9604 was tested in oral form in the Phase IIa and IIb human trials — unusual for a peptide, which typically has poor oral bioavailability due to gastrointestinal digestion. Oral bioavailability in rat models was estimated at approximately 40%, enabling encapsulated tablet form in human trials [9]. The More and Kenley 2014 nutraceutical paper specifically characterized oral bioavailability and safety in pig pharmacokinetic models: peak plasma concentration of 1,127 ng/mL was reached at approximately 60 minutes post-dose [10]. Intravenous administration was the route used in Phase I dose-escalation studies [4]. Intra-articular injection (0.25 mg weekly) was studied in the rabbit osteoarthritis model [11]. Subcutaneous injection is used in research settings; no published peer-reviewed pharmacokinetic data exists for the subcutaneous route in humans. Oral vs subcutaneous AOD9604 administration is covered in full above.
AOD9604 Half-Life and Pharmacokinetic Profile
No precise plasma half-life has been published in peer-reviewed literature for subcutaneous AOD9604 in humans. IV half-life in pig pharmacokinetic studies is approximately 3 minutes [18]. Oral Tmax in pig pharmacokinetic studies is approximately 60 minutes post-dose [10]. No subcutaneous human half-life data has been published. Researchers citing specific subcutaneous human half-life values are extrapolating beyond the published record.
What Cycle Lengths Were Studied in Research?
The longest published human study ran 24 weeks: the Phase IIb OPTIONS trial, which evaluated daily oral AOD9604 at three doses against placebo [8]. Chronic animal toxicology studies ran 6 months in rats (NOAEL established at 100 mg/kg/day) and 9 months in cynomolgus monkeys (NOAEL 50 mg/kg/day) [9]. No adverse long-term safety signals were identified in any published study window. Research beyond 24 weeks in humans has not been published.
AOD9604 Storage and Reconstitution
As a lyophilized peptide, research-grade AOD9604 is typically stored at -20°C in powder form. Reconstituted solution is stored at 2–8°C. Specific stability data under various storage conditions has not been published in the primary clinical literature [9].
How Long Does It Take for AOD9604 to Start Working?
Research protocols studied response windows of 12–24 weeks. Preclinical models showed measurable lipolytic effects within 2–4 weeks of continuous treatment [1][10]. No validated human onset-of-effect timeline exists from controlled trials. The pig pharmacokinetic data shows peak plasma concentration at approximately 60 minutes post-oral-dose [10], but that is a pharmacokinetic parameter, not an efficacy onset measurement.
AOD9604 Combination Research: Stacking Considerations
The most documented co-administration in the published literature is AOD9604 plus hyaluronic acid for intra-articular injection in the rabbit OA model — that combination produced superior cartilage outcomes versus either agent alone [11]. No published clinical or preclinical studies specifically examine AOD9604 plus ipamorelin co-administration. Their mechanisms are distinct (direct adipocyte lipolysis versus GH secretagogue) but the safety and pharmacokinetic interaction profile has not been characterized in the research literature [16].